IP Library Granted Patent US 10,675,270
Granted Patent B2
US 10,675,270 · App. 16/124,269 · Granted Jun 9, 2020

Chondroitin complexes for transcutaneous absorption

Inventors: Mario De Rosa (Lugano, CH); Chiara Schiraldi (Lugano, CH)
Assignee: Altergon S.A.
A61K31/407A61K8/735A61K9/0014A61K9/06A61K31/196A61K47/36A61K47/61A61Q19/08A61K2800/54
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,675,270
App. No.
16/124,269
Granted
Jun 9, 2020
Kind
B2
Abstract

The present invention relates to the use of chondroitin as a transdermal carrier and slow-release system for active ingredients in pharmaceutical and cosmeceutical compositions.

Claims (7)

1. A method of transdermal or trans-mucosa delivery of a non-covalent complex of non-sulphated chondroitin having a molecular weight between 5 and 100 kDa determined by size exclusion chromatography and an active ingredient in a patient in need thereof, said method comprising

applying said complex on said skin or on said mucosa of said patient; and

obtaining said transdermal or transmucosa delivery of said complex, wherein said complex is absorbed through mucous membranes or skin and wherein said complex behaves as transdermal carrier and slow-release system for said active ingredient.

2. The method according to claim 1 , wherein the active ingredient is a non-steroidal or steroidal anti-inflammatory, an antitumoral, an antiviral, an antimicrobial, a diuretic, a contraceptive, an analgesic, a bronchodilator, a monoclonal antibody, an immunosuppressant, a vasoconstrictor or a vasodilator, an antioxidant, a soothing, moisturising or draining agent, a biostimulant, a radical scavenger, a wrinkle treatment agent, a hair growth compound or a bioactive peptide, or combinations thereof.

3. The method according to claim 1 , wherein said complex is administered topically, nasally, rectally or vaginally.

4. The method according to claim 1 wherein said complex is in the form of solutions, emulsions, gel, creams, sprays, suppositories, eyedrops, masks, patches, dressings and plasters.

5. The method according to claim 1 , wherein said non-sulphated chondroitin behaves as a transdermal carrier and slow-release system for said active ingredient.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2025
From: ALTERGON SA
To: IBSA INSTITUT BIOCHIMIQUE SA
Reel/Frame 071736/0261 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2018
From: DE ROSA, MARIO; SCHIRALDI, CHIARA
To: ALTERGON S.A.
Reel/Frame 046810/0099 →
Priority Claims (1)
IT MI2012A1316 · Jul 27, 2012 · national
Continuity (2)
Division 14416669
Related Publication 20190000803A1 · Jan 3, 2019